

1222·2022  
**800**  
ANNI



UNIVERSITÀ  
DEGLI STUDI  
DI PADOVA



**FeSDI**  
ALLEANZA PER IL DIABETE

# DIABETE MELLITO E MALATTIA CARDIOVASCOLARE. LE LINEE GUIDA SID-AMD

Angelo Avogaro

Dipartimento di Medicina

Università di Padova

**Il sottoscritto ANGELO AVOGARO  
ai sensi dell'art. 3.3 sul Conflitto di Interessi, pag. 17 del Reg.  
Applicativo dell'Accordo Stato-Regione del 5 novembre 2009,**

**Dichiara**



**che negli ultimi due anni ha avuto rapporti diretti di  
finanziamento con i seguenti soggetti portatori di interessi  
commerciali in campo sanitario:**

**Novo Nordisk, Astrazeneca, Bayer, Boehringer-Ingelheim, Servier, Lilly,  
Sanofi, Takeda, MSD, Novartis, Allergan, GSK**

# New Paradigm of Management of the **Cardiometabolic Continuum**




NEW SID-AMD  
Italian Guidelines for  
**Diabetes**  
Management July  
2021




# Relative Importance of Risk Factors for Predicting Death from Acute Myocardial Infarction, among Patients with Type 2 Diabetes

## B Acute Myocardial Infarction



# Factors associated with LDL-c levels < 70 mg/dl in patients without and with diabetes.



# Clinical Inertia in People with Type 2 Diabetes

81,573 people with type 2 diabetes in the U.K. Clinical Practice Research Datalink between January 2004 and December 2006, with follow-up until April 2011

